Techbio firm Evaxion posts Q3 net income of $4.6 mln

Reuters

Nov 06

Techbio firm Evaxion posts Q3 net income of $4.6 mln

Overview

Evaxion Q3 net income $4.6 mln, a turnaround from $1.9 mln loss last year
Revenue of $7.5 mln in Q3, primarily from MSD option exercise
Evaxion extends cash runway to second half of 2027 after MSD payment

Outlook

Company highlights ongoing partnership discussions amid financial market uncertainties
Evaxion extends cash runway to second half of 2027
Company aims to enter at least one more partnership deal in coming months

Result Drivers

Research and development (R&D) expenses were $3.1 million for the period ending September 30, 2025, compared to $2.6 million last year

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		$4.62 mln
Q3 Basic EPS		$0.01
Q3 Pretax Profit		$4.35 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Evaxion A/S is $11.00, about 48.5% above its November 5 closing price of $5.66

Press Release: ID:nGNX94BchG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581509839"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581509839\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581509839?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581509839","market":"fut","top_or_hot":-1,"title":"Techbio firm Evaxion posts Q3 net income of $4.6 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Techbio firm Evaxion posts Q3 net income of $4.6 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Evaxion Q3 net income $4.6 mln, a turnaround from $1.9 mln loss last year</p></li><li><p>Revenue of $7.5 mln in Q3, primarily from MSD option exercise</p></li><li><p>Evaxion extends cash runway to second half of 2027 after MSD payment</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company highlights ongoing partnership discussions amid financial market uncertainties</p></li><li><p>Evaxion extends cash runway to second half of 2027</p></li><li><p>Company aims to enter at least one more partnership deal in coming months</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses were $3.1 million for the period ending September 30, 2025, compared to $2.6 million last year</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$4.62 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>$0.01</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>$4.35 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Evaxion A/S is $11.00, about 48.5% above its November 5 closing price of $5.66</p></li></ul><p>Press Release: <span>ID:nGNX94BchG</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Techbio firm Evaxion posts Q3 net income of $4.6 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTechbio firm Evaxion posts Q3 net income of $4.6 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Techbio firm Evaxion posts Q3 net income of $4.6 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Evaxion Q3 net income $4.6 mln, a turnaround from $1.9 mln loss last year</p></li><li><p>Revenue of $7.5 mln in Q3, primarily from MSD option exercise</p></li><li><p>Evaxion extends cash runway to second half of 2027 after MSD payment</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company highlights ongoing partnership discussions amid financial market uncertainties</p></li><li><p>Evaxion extends cash runway to second half of 2027</p></li><li><p>Company aims to enter at least one more partnership deal in coming months</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses were $3.1 million for the period ending September 30, 2025, compared to $2.6 million last year</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$4.62 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>$0.01</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>$4.35 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Evaxion A/S is $11.00, about 48.5% above its November 5 closing price of $5.66</p></li></ul><p>Press Release: <span>ID:nGNX94BchG</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVAX","symbol_name":"Evaxion Biotech A/S","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0OI:1","article_id":"2581509839","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581509839","pubTimestamp":1762433067,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Techbio firm Evaxion posts Q3 net income of $4.6 mlnOverviewEvaxion Q3 net income $4.6 mln, a turnaround from $1.9 mln loss last yearRevenue of $7.5 mln in Q3, primarily from MSD option exerciseEvaxio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVAX":"Evaxion Biotech A/S","BK4139":"生物科技"},"translate_title":"Techbio公司Evaxion公布第三季度净利润为460万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVAX":0.9},"content_text":"Techbio firm Evaxion posts Q3 net income of $4.6 mlnOverviewEvaxion Q3 net income $4.6 mln, a turnaround from $1.9 mln loss last yearRevenue of $7.5 mln in Q3, primarily from MSD option exerciseEvaxion extends cash runway to second half of 2027 after MSD paymentOutlookCompany highlights ongoing partnership discussions amid financial market uncertaintiesEvaxion extends cash runway to second half of 2027Company aims to enter at least one more partnership deal in coming monthsResult DriversResearch and development (R&D) expenses were $3.1 million for the period ending September 30, 2025, compared to $2.6 million last yearKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income$4.62 mlnQ3 Basic EPS$0.01Q3 Pretax Profit$4.35 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Evaxion A/S is $11.00, about 48.5% above its November 5 closing price of $5.66Press Release: ID:nGNX94BchGFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}